Mixed-cell gene therapy

Details Mixed-cell gene therapy Mixed-cell gene therapy

2006-02-28

2006-02-28

Sullivan, Daniel M. (Department: 1636)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093200, C424S093300, C435S347000, C514S04400A

Reexamination Certificate

active

07005127

ABSTRACT:
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.

REFERENCES:
patent: 5700774 (1997-12-01), Hattersley et al.
patent: 5766585 (1998-06-01), Evans et al.
patent: 5842477 (1998-12-01), Naughton et al.
patent: 5846931 (1998-12-01), Hattersley et al.
patent: 5858355 (1999-01-01), Glorioso et al.
patent: 6315992 (2001-11-01), Noh et al.
patent: 6413511 (2002-07-01), Glorioso et al.
patent: 6797703 (2004-09-01), Noh et al.
patent: WO 00/66177 (2000-11-01), None
Groomer et al. High-efficiency non-viral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects. Osteoarthritis Cartilage. Apr. 2001;9(3):248-56.
van Beuningen et al. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-beta injections. Osteoarthritis Cartilage. Jan 2000;8(1):25-33.
Bakker et al. Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. Osteoarthritis Cartilage. Feb. 2001;9(2):128-36.
Brittberg et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. Oct. 6, 1994;331(14):889-95.
Valcourt et al. Different effects of bone morphogenetic proteins 2, 4, 12, and 13 on the expression of cartilage and bone markers in the MC615 chondrocyte cell line. Exp Cell Res. Sep. 15, 1999;251(2):264-74.
Fukui et al. Cell biology of osteoarthritis: the chondrocyte's response to injury. Curr Rheumatol Rep. Dec. 2001;3(6):496-505.
Evans et al. Osteoarthritis gene therapy. Gene Ther. Feb. 2004;11(4):379-89.
Evans, C.H. Gene therapies for osteoarthritis. Curr Rheumatol Rep. Feb. 2004;6(1):31-40.
Chang et al. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev. Dec. 2002;23(6):787-823.
Lee et al, “Regeneration of Hyaline Cartilage by Cell-Mediated Gene Therapy Using Transforming Growth Factor Beta1-Producing Fibroblasts”, Human Gene Therapy, vol. 12, pp. 1805-1813 (2001).

Affiliated with

Also associated with

Rating

Mixed-cell gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mixed-cell gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixed-cell gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3697034